Latest Financial Position News

Challenger Gold Limited’s major shareholder, the Elsztain Group, has increased its commitment in the company’s institutional placement, raising the total capital raise to $37.5 million. This move signals strong insider confidence ahead of a shareholder vote.

Aeris Resources reported a robust June 2025 quarter with increased copper and gold production, improved cost efficiencies, and successful refinancing, while advancing exploration at key projects.

Amaero Ltd reports solid June quarter revenue and signs a pivotal five-year exclusive supply agreement with Velo3D, underpinning its growth outlook and updated EBITDA guidance for FY2027.

Beacon Minerals has announced a $12 million on-market share buy-back program aiming to enhance shareholder value and capital efficiency, with purchases starting August 1, 2025.

Cleo Diagnostics reports steady progress in its ovarian cancer diagnostic test development, with clinical trial recruitment on track and strategic access to major biobanks enhancing its regulatory pathway.

Elixir Energy has advanced its strategic plan in Queensland’s Taroom Trough, appointing a new COO, initiating a major cost reduction, and preparing to drill key exploration and appraisal wells that could unlock significant gas resources.

Norwood Systems delivered its strongest quarter yet with record cash inflows, significant debt reduction, and expanding global partnerships, setting a robust foundation for FY2026.

Lumos Diagnostics reported a 12% revenue increase for FY25 and inked a landmark US$317 million exclusive distribution deal for its FebriDx test, while advancing its FDA CLIA waiver application.

Copper Search Limited made significant strides in the June 2025 quarter, revealing promising Heavy Mineral Sands potential in South Australia and securing a strategic option over a major NSW gold-copper project, while raising $1.15 million to fuel its exploration ambitions.

Aura Energy has marked significant progress toward uranium production at its Tiris project in Mauritania, while forging a key collaboration to advance uranium exploration in Sweden amid shifting regulatory landscapes.

PYC Therapeutics reports solid progress across its four RNA therapeutic programs targeting genetic diseases, backed by a strong cash position extending runway beyond 2027.

PlaySide Studios has released its unaudited FY25 results, showing revenues just below guidance and an EBITDA loss within expectations amid restructuring. The company remains optimistic about revenue growth and cost savings in FY26, pending the launch of its new title.